Literature DB >> 15990620

Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria.

.   

Abstract

Ulcerative colitis and Crohn disease may present before the age of 20 years in 25% to 30% of all patients with inflammatory bowel disease. Reported incidence figures vary considerably depending on the collection of data. Multicenter, multinational collaboration is needed when studying pediatric inflammatory bowel disease. The essential first step is uniformity in the work-up and criteria used for diagnosis. The Porto diagnostic criteria presented here provide the tool that is needed. These criteria are the result of consensus reached by the ESPGHAN inflammatory bowel disease working group. Diagnosis of Crohn disease, ulcerative colitis and indeterminate colitis is based on clinical signs and symptoms, endoscopy and histology and radiology. Every child suspected of inflammatory bowel disease should undergo a complete diagnostic program consisting of colonoscopy with ileal intubation, upper gastrointestinal endoscopy and (in all cases except in definite ulcerative colitis) radiologic contrast imaging of the small bowel. Multiple biopsies from all segments of the gastrointestinal tract are needed for a complete histologic evaluation. A diagnosis of indeterminate colitis cannot be made unless a full diagnostic program has been performed.

Entities:  

Mesh:

Year:  2005        PMID: 15990620     DOI: 10.1097/01.mpg.0000163736.30261.82

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  173 in total

Review 1.  Inflammatory bowel disease.

Authors:  R M Beattie; N M Croft; J M Fell; N A Afzal; R B Heuschkel
Journal:  Arch Dis Child       Date:  2006-05       Impact factor: 3.791

2.  Efficacy of early treatment with infliximab in pediatric Crohn's disease.

Authors:  Jong Seung Lee; Jee Hyun Lee; Ji Hyuk Lee; Hye Jin Lee; Mi Jin Kim; Hae Jeong Lee; Yon Ho Choe
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

3.  Response to Fuller-Thomson.

Authors:  Eric I Benchimol; David R Mack; Geoffrey C Nguyen
Journal:  Am J Gastroenterol       Date:  2015-09       Impact factor: 10.864

4.  Immune response to influenza vaccine in children with inflammatory bowel disease.

Authors:  Ying Lu; Denise L Jacobson; Lori A Ashworth; Richard J Grand; Anthony L Meyer; Monica M McNeal; Matt C Gregas; Sandra K Burchett; Athos Bousvaros
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

5.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

Review 6.  Diagnosis and management of inflammatory bowel disease in children.

Authors:  Stephanie B Oliveira; Iona M Monteiro
Journal:  BMJ       Date:  2017-05-31

7.  Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis.

Authors:  Ondrej Fabian; Ondrej Hradsky; Tereza Drskova; Filip Mikus; Josef Zamecnik; Jiri Bronsky
Journal:  Dig Dis Sci       Date:  2018-03-14       Impact factor: 3.199

8.  Vitamin D status in children and young adults with inflammatory bowel disease.

Authors:  Helen M Pappa; Catherine M Gordon; Tracee M Saslowsky; Anna Zholudev; Brian Horr; Mei-Chiung Shih; Richard J Grand
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

Review 9.  Inflammatory bowel disease and celiac disease: overlaps and differences.

Authors:  Virginia Pascual; Romina Dieli-Crimi; Natalia López-Palacios; Andrés Bodas; Luz María Medrano; Concepción Núñez
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 10.  Special issues in pediatric inflammatory bowel disease.

Authors:  Marla Dubinsky
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.